As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks

Application expands Artelo’s intellectual property position for ART27.13 into obesity, where J.P. Morgan has projected the global GLP-1 market could reach $200 billion by 2030

New findings show the combination further improved oral glucose tolerance and increased bone mineral density, an effect not observed in any other treatment group

SOLANA BEACH, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with obesity, cancer, pain, dermatologic and neurological conditions, today announced the filing of a provisional patent application covering the use of ART27.13 for the treatment of obesity. The application covers ART27.13 both as a monotherapy and in combination with GLP-1 receptor agonists such as semaglutide, the active ingredient in Ozempic® and Wegovy®.

The filing follows unexpected findings from Artelo’s nonclinical DIO-2 study that point to a potentially broader role for ART27.13 in weight and metabolic regulation. The Company is disclosing additional findings from the study today, alongside results reported on September 16, 2026.

As previously reported, ART27.13 monotherapy produced approximately 20% weight loss from baseline over four weeks in obese mice, comparable to semaglutide. In combination with semaglutide, obese mice lost approximately 40% of their baseline body weight. Approximately 80% of the weight lost in ART27.13-treated groups was fat, compared with approximately 70% with semaglutide alone.

The new findings show that the combination suppressed appetite more than semaglutide alone and further improved oral glucose tolerance. Bone mineral density increased in the combination group, an effect not observed in any other treatment group. Semaglutide and ART27.13 each reduced total cholesterol, LDL and HDL to similar extents, with greater reductions when given together. Liver hypertrophy was reduced across all treatment groups.